[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645232":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":45,"centralContacts":50,"locations":60,"responsibleParty":79,"collaborators":81,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":10,"enrollmentInfo":95,"targetDuration":10,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":107,"whyStopped":10,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Fresenius Medical Care Deutschland GmbH","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AKI patients",null,"Patients with acute Kidney Injury (AKI) with clinical indication for CKRT",[13,14,15,16,17,18],"Device: multiFlux 160 hemofilter with regional heparin anticoagulation","Device: multiFlux 160 hemofilter with RCA with regional citrate anticoagulation","Device: multiFlux 130 hemofilter with regional heparin anticoagulation","Device: multiFlux 130 hemofilter with RCA with regional citrate anticoagulation","Device: multiFlux 60 hemofilter with regional heparin anticoagulation","Device: multiFlux 60 hemofilter with RCA with regional citrate anticoagulation",[20,25,29,33,37,41],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DEVICE","multiFlux 160 hemofilter with regional heparin anticoagulation","Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"multiFlux 160 hemofilter with RCA with regional citrate anticoagulation","Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)",[9],{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"multiFlux 130 hemofilter with regional heparin anticoagulation","Extracorporeal blood purification with the multiFlux 130 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)",[9],{"type":21,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"multiFlux 130 hemofilter with RCA with regional citrate anticoagulation","Extracorporeal blood purification with the multiFlux130 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)",[9],{"type":21,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"multiFlux 60 hemofilter with regional heparin anticoagulation","Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)",[9],{"type":21,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"multiFlux 60 hemofilter with RCA with regional citrate anticoagulation","Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)",[9],[46],{"name":47,"affiliation":48,"role":49},"Christina Scharf-Janßen, PD Dr. med.","LMU University Hospital","PRINCIPAL_INVESTIGATOR",[51,56],{"name":52,"role":53,"phone":54,"phoneExt":10,"email":55},"Celina Meyer","CONTACT","+49 6172 268 6809","Celina.Meyer@FreseniusMedicalCare.com",{"name":57,"role":53,"phone":58,"phoneExt":10,"email":59},"Anja Derlet-Savoia, Dr.","+49 6172 268 6648","Anja.Derlet@freseniusmedicalcare.com",[61],{"facility":62,"status":10,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)","Munich","Bavaria","81377","Germany","DE",{"type":69,"coordinates":70},"Point",[71,72],11.57549,48.13743,{"lat":72,"lon":71},[75],{"name":76,"role":53,"phone":77,"phoneExt":10,"email":78},"Christina Christina Scharf-Janßen, Dr. med.","089-4400-84163","christina.scharf-janssen@med.uni-muenchen.de",{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[82],{"name":83,"class":84},"Mediconomics GmbH","UNKNOWN","100645232","analysis-of-continuous-kidney-replacement-therapy-ckrt-treatments-with-multiflux-hemofilters-using-regional-citrate-anticoagulation-rca-or-systemic-heparin-anticoagulation-100645232",false,"NCT07679568","Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation","Analysis of CKRT Treatments With multiFlux Hemofilters Using RCA or Systemic Heparin Anticoagulation","RCA-Flux","Inclusion Criteria:\n\nGeneral:\n\nPatients ≥ 18 years:\n\n* Informed consent signed and dated by the investigator; and\n\n  1. if patient is able to give consent: by the study patient\n  2. if patients unable to give consent: by the legal representative\u002Fspouse according to § 1358 BGB or\n  3. if an emergency situation is determined: by an independent consultant physician.\n\n     Pediatric Patients \\\u003C 18 years:\n* Informed consent signed and dated by legal representative and investigator\u002F authorized physician.\n* The minors have received the information referred to in Article 63(2) Medical Device Regulation (MDR) in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children. If able, the minors have to sign the informed consent, too.\n* The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator\n\nStudy specific:\n\n* Body weight ≥ 8kg\n* Acute Kidney Injury (AKI) with clinical indication for CKRT\n* Clinically estimated life expectancy greater than 3 days\n\nExclusion Criteria:\n\n* Any conditions which could interfere with the patient's ability to comply with the study\n* Patient or legal representative or authorized physician during emergency situation is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations\n* Participation in a different interventional clinical study during the preceding 30 days\n* Previous participation in the same study\n* Uncontrolled bleeding and coagulation disorders","ALL","1 Year",{"count":96,"type":97},62,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments. The multiFlux hemofilter is a single use device within the extracorporeal blood circuit during extracorporeal blood purification treatments for acute renal replacement therapies.",[101,102],"Acute Kidney Injury","Renal Failure",[104,105,106],"Continuous kidney replacement therapy","Regional citrate anticoagulation","Systemic heparin anticoagulation","NOT_YET_RECRUITING","2026-06-25",{"date":110,"type":111},"2026-07-01","ACTUAL",{"date":113,"type":97},"2026-07",{"date":115,"type":97},"2027-12",{"name":5,"class":6},1]